R espiratory syncytial virus (RSV) is one of the last remaining highly prevalent childhood pathogens without an approved vaccine. It is estimated to be responsible for 6.7% of deaths in children 1 month to 1 year of age and causes excess mortality in the elderly at levels comparable to influenza virus (1) . Although RSV infection does not induce fully protective immunity, antibodies against the RSV fusion (F) glycoprotein can prevent severe disease in humans as demonstrated by passive prophylaxis with the F-directed antibody, palivizumab (Synagis) (2) .
The proven success of palivizumab (3) has spurred vaccine efforts aimed at eliciting protective RSV F-directed antibodies. These efforts have been complicated by the conformational diversity of RSV F (4-8), a type I fusion glycoprotein that merges virus and host-cell membranes by using the difference in folding energy between two substantially different states: a metastable state adopted before virus-cell interaction (prefusion) and a stable state that occurs after merging of virus and cell membranes (postfusion). Both states exhibit epitopes targeted by neutralizing antibodies, and postfusion RSV F is being developed as a vaccine candidate (6, 9) . Recently, however, the major target of RSV-neutralizing antibodies elicited by natural infection was found to reside primarily on the prefusion conformation of RSV F (10) . Antibodies such as 5C4 (7), AM22, and D25 (11, 12) are substantially more potent than palivizumab and target antigenic site 0 / (zero), a metastable site located at the membrane-distal apex of the prefusion RSV F trimer (7) .
To enhance elicitation of similarly potent antibodies, we engineered soluble variants of RSV F with stably exposed antigenic site 0 /. These variants were characterized antigenically and crystallographically and tested for immunogenicity in mice and nonhuman primates (rhesus macaques).
Structure-Based Vaccine Strategy
We and others have engineered antigenicity (13) (14) (15) (16) (17) through structure-based design of the epitopes recognized by template neutralizing antibodies. For example, the crystal structure of motavizumab (a variant of palivizumab) bound to its F glycoprotein epitope (18) allowed us to create epitope scaffolds, which stably presented the motavizumab epitope on heterologous proteins (19) . Although motavizumab-epitope scaffolds could elicit immune responses that recognized F, substantial neutralizing activity was not induced (19) . We hypothesized that instead of a single epitope recognized by a single template antibody, it would be advantageous to present a "supersite" (20) , comprising a collection of overlapping epitopes recognized by multiple antibodies. Even more preferable would be for such a site to be ultrasensitive to neutralization. These considerations led to a "neutralization-sensitive site" strategy: (i) to identify a viral site targeted by multiple antibodies with extremely potent neutralizing activity, (ii) to determine the structure of the site in complex with a representative antibody, (iii) to engineer the stable presentation of the site in the absence of recognizing antibody, and (iv) to elicit high-titer protective responses through immunization with engineered antigens that stably present the neutralization-sensitive site ( fig. S1 ).
Engineering of RSV F Antigens
Antigenic site Ø was chosen as the target site because of its recognition by RSV-neutralizing antibodies that are 10-to 100-fold more potent than palivizumab (7, 11, 12) . We previously determined the structure of antigenic site Ø in complex with the D25 antibody (7). Structure determination involved appending the T4-phage fibritin trimerization domain ("foldon") (21, 22) to the C terminus of the RSV F ectodomain (5) and binding of the prefusion-specific D25 antibody. Although these approaches stabilized antigenic site Ø, D25 binding sterically occluded the target site. To stably present antigenic site Ø in the absence of D25, we retained the C-terminal trimerization domain and combined it with other means of stabilization, including the introduction of cysteine pairs or cavity-filling hydrophobic substitutions.
The b-carbons of serine residues 155 and 290 are 4.4 Å apart in the D25-bound RSV F structure (7) and 124.2 Å apart in the postfusion structure (5) (Fig. 1 and fig. S2 ). A S155C-S290C double mutant (DS) [in which cysteine replaced serine at positions 155 and 290 (23)] formed stable RSV F trimers, expressed at 1.4 mg/liter, retained antigenic site Ø, and was homogeneous as judged by negative-stain electron microscopy (Table 1 and fig. S3 ) (24, 25). Other intrachain cysteine modifications, such as those between regions of RSV F that do not rearrange between pre-and postfusion states (e.g., S403C and T420C), did not stabilize antigenic site Ø (Table 1) . We also tested potential interchain double-cysteine modifications, but none expressed at levels sufficient for enzyme-linked immunosorbent assay (ELISA) detection (table S1) (26).
We analyzed the D25-bound RSV F structure for hydrophobic cavities unique to the D25-bound conformation of RSV F that abutted regions that differed in the prefusion and postfusion states (27). Several such cavities were identified in the membrane-distal "head" of the prefusion structure, close to the binding site of D25, and we engineered hydrophobic substitutions to fill these cavities. S190F and V207L substitutions were predicted to adopt prevalent side-chain conformations with minimal clashes, whereas K87F, V90L, V220L, and V296F showed less steric compatibility. We assessed the impact of filling these cavities with pairs of changed residues. A S190F-V207L pair (Cav1) (Fig. 1) , formed stable RSV F trimers, expressed at 2.2 mg/liter, and retained antigenic site Ø (Table 1) . Moreover, K87F-V90L, S190F-V296F, and V207L-V220L variants showed enhanced retention of D25 recognition but expressed at less than 0.1 mg/liter (Table 1) .
Other cavities we identified toward the center of prefusion RSV F were close to the fusion peptide, the trimer axis, and an acidic patch comprising residues Asp 486 , Glu
487
, and Asp
489
. We modeled several cavity-filling substitutions, including F137W, F140W, and F488W, and analyzed these substitutions in combination with D486H, E487Q, and D489H (table S1). Of the six combinations tested, only two (F488W and D486H-E487Q-F488W-D489H) expressed levels of purified RSV F trimer at greater than 0.1 mg/liter and retained D25 recognition. The D486H-E487Q-F488W-D489H variant (TriC) formed stable RSV F trimers, expressed at 0.8 mg/liter, and retained antigenic site Ø ( Fig. 1 and Table 1 ).
We also tested the impact of destabilizing the postfusion conformation on the preservation of antigenic site Ø. The substitution V178N, which is predicted to introduce an N-linked glycan compatible with the prefusion but not the postfusion conformation of F, did not appear to stabilize antigenic site Ø, nor did V185E or I506K, which were predicted to place a glutamic acid or a lysine into the interior of the postfusion six-helix bundle (Table 1 ). In all, more than 100 RSV F variants were constructed (table S1), expressed in a 96-well transfection format (28) ( fig. S4) , and tested by ELISA of the culture supernatants for binding to D25 and motavizumab (figs. S5 and S6). Fifteen constructs were compatible with D25 binding, four of which retained D25 recognition for at least 7 days at 4°C, and three of these could be purified as homogeneous trimers that retained antigenic site Ø (table S1 and fig. S7 ). Overall, we observed a strong correlation between retention of D25 binding for at least 7 days at 4°C in 96-well supernatants and yield of purified trimers after large-scale expression and purification ( fig. S5 ).
Combinatorial Optimization of Site Ø Stability DS, Cav1, and TriC variants displayed a variety of physical and antigenic properties. The DS variant was the least stable to pH and temperature variation but was more permanently stabilized in the trimeric state, whereas a low level of continual conversion from trimer to aggregate was observed for Cav1 and TriC on size-exclusion chromatography. Combinations of the three variants improved retention of D25 reactivity to physical extremes, a characteristic helpful to manufacturing. Overall, the DS-Cav1 combination appeared optimal in terms of trimer yield and physical stability to extremes of temperature, pH, osmolality, and freeze-thaw (Table 1) , and was homogeneous as judged by negative-stain electron microscopy ( fig. S2 ).
Crystallographic Analysis
To provide atomic-level information, we determined crystal structures of site Ø-stabilized variants of RSV F (Fig. 2) . The DS, Cav1, DS-Cav1, and DS-Cav1-TriC variants all crystallized in similar 1.5 M tartrate (pH 9.5) conditions, and these cubic crystals diffracted x-rays to resolutions of 3.2 Å, 3.1 Å, 3.1 Å, and 2.8 Å, respectively (table S2). Molecular replacement solutions were obtained by using the D25-bound RSV F structure as a search model, and these revealed a single RSV F protomer in the asymmetric unit, with the trimeric F axis aligned along the crystallographic three-fold axis. Tetragonal crystals of Cav1 and cubic crystals of DS-Cav1 were also obtained from 1.7 M ammonium sulfate (pH 5.5) conditions, and these diffracted to resolutions of 2.4 Å and 3.0 Å, respectively (table S2). Molecular replacement revealed the tetragonal lattice to have a full RSV F trimer in the asymmetric unit and to be highly related to the tartrate cubic lattices. Overall, these structures revealed the engineered RSV F variants to be substantially in the D25-bound conformation (29).
Although the structure of the DS variant ( Fig. 2 , left column) revealed that the cysteine-substituted residues at 155 and 290 formed a disulfide bond that prevented triggering to the postfusion state, much of the membrane-distal portion of the RSV F trimer, including antigenic site Ø, was either disordered (residues 63 to 72 and 169 to 216) or in a different conformation. Thus, for example, residues 160 to 168 in the DS structure extended the a2 helix instead of forming a turn and initiating the a3 helix, as in the D25-bound F structure (Fig. 2C, left) . One possible explanation for the differences between the DS structure and the D25-bound RSV F structure is that antigenic site Ø in DS is flexible and crystallized in a conformation that does not bind D25 (30). Overall, the DS variant retained many of the features of the prefusion state of RSV F, including the fusion peptide in the interior of the trimeric cavity; however, it failed to fix antigenic site Ø in its D25-bound conformation ( fig. S8 ).
In comparison with DS, the Cav1 structure (Fig. 2 , second and third columns) was more ordered at its membrane-distal apex, with a3 helix, b3/b4 hairpin, and a4 helix clearly defined. Residues 137 to 202, which contain the S190F substitution, had a Ca root mean square deviation of 0.6 Å when compared with the D25-bound F structure. The higher degree of structural order was likely due to the S190F mutation that filled a cavity observed in the D25-bound F structure and increased van der Waals contacts with residues Ile . The other cavity-filling mutation in Cav1, V207L, was shifted by 5.5 Å compared with the D25-bound F structure, with the C-terminal portion of the Fig. 1 . DesignofsolublesiteØ-stabilized RSV F trimers. Over 100 variants of RSV F containing the T4 fibritin-trimerization domain (foldon) were designed to provide greater stability to antigenic site Ø (table S1). Shown here is the structure of the RSV F trimer in its D25-bound conformation with modeled C-terminal foldon. The trimer is displayed with two of the three F 1 F 2 protomers in molecular surface representation (colored tan and pink), and the third F 1 F 2 protomer in ribbon representation. The ribbon is colored gray in regions where it is relatively fixed between pre-and postfusion, and the N-and C-terminal residues that move more than 5 Å between pre-and postfusion conformations are colored blue and green, respectively. Mutations compatible with RSV F expression and initial D25 recognition (table S1), but insufficiently stable to allow purification of RSV F as a homogenous trimer (Table 1) , are labeled and shown in stick representation (colored black). Insets show enlargements of stabilizing mutations in stick representation (colored red) for DS, Cav1, and TriC variants, all of which sufficiently stabilize antigenic site Ø to allow purification as a homogeneous trimer (Table 1) .
www.sciencemag.org SCIENCE VOL 342 1 NOVEMBER 2013 593 RESEARCH ARTICLE a4 helix kinking near Pro 205 and adopting distinct conformations in the two crystallization conditions (Fig. 2, second and third columns) , which suggested that the V207L mutation is unable to stabilize the a4 helix in the D25-bound conformation.
A striking feature of the Cav1 structure in the tetragonal crystal lattice was the C terminus of F 2 , which is disordered in the D25-bound F structure, but in Cav1, tunnels into the trimeric cavity alongside the fusion peptide. We also observed the C terminus to end with Ala ) (31) . In the Cav1 structure, the positive charge of Arg 106 was offset by an ordered sulfate ion (Fig. 2C) . Biologically, the interior position of the F 2 C terminus may play a role in triggering structural rearrangements of F.
Comparison of the DS-Cav1 structures from the two cubic crystal forms (Fig. 2 , second and third columns from right) to those of Cav1 revealed only minor differences (32) . The largest differences occurred at the RSV F apex, including antigenic site Ø and specifically at residues 64 to 73 and 203 to 216. Notably, the atomic mobility (B-factor) was highest in this apex region for all of the site Ø-stabilized variants, perhaps indicative of intrinsic site Ø flexibility. However, site Ø has low atomic mobility when bound by D25, which reveals the ability of D25 to stabilize both overall and local RSV F conformations.
The structure of the DS-Cav1-TriC triple combination (Fig. 2, far right column) was also highly similar to other Cav1-containing RSV F variant structures. One difference in the electron density corresponded to an expanse of weak density at the membrane-proximal region, which approximated the dimensions of the T4-fibritin trimerization domain (33) but was not visible in other crystallized RSV F structures containing this domain, including the D25-bound structure (7) . Small structural differences in packing likely allowed for the partial ordering of this domain (and may also have accounted for the increased diffraction limit of the DS-Cav1-TriC crystals relative to the other cubic variants), rather than differences in the interaction between the DSCav1-TriC stabilized RSV F and the trimerization domain.
The critical F488W substitution in the TriC alteration of residues 486 to 489 packed directly against the F488W substitutions in neighboring protomers of the RSV F trimer. The indole side chain of Trp 488 pointed toward the trimer apex and also formed ring-stacking interactions with the side chain of Phe 140 of the fusion peptide (Fig. 2C, far right) . This fusion peptide interaction, which is not observed in any of the Phe 488 -containing structures, likely inhibits the extraction of the fusion peptide from the prefusion trimer cavity and thus provides a structural rationale for the ability of the F488W substitution to stabilize the prefusion state of RSV F ( Table 1) .
Immunogenicity of Antigenic Site Ø-Stabilized RSV F To assess the effect of site Ø stabilization on the elicitation of RSV-protective humoral responses, we immunized CB6F1/J mice with various forms of RSV F, injecting each mouse with 10 mg RSV F combined with 50 mg polyinosinic-polycytidylic acid stabilized with polylysine carboxymethylcellulose (poly- (Fig. 3A) .
To quantify antibody responses to different sites on prefusion RSV F, we used antigenic site Ø-occluded forms of RSV F. CB6F1/J mice immunized with 20 mg RSV F bound by antigenic site Ø-directed antibodies (comprising~10 mg of RSV F and~10 mg of the antigen-binding fragment of antibody) developed at week 5 geometric Table 1 . Antigenic and physical properties of engineered RSV F glycoprotein variants. Variants were often observed to exist in a mixture of oligomeric states on size-exclusion chromatography. If a measureable trimeric fraction was observed, then this is indicated by the label "Trimer," and the various properties of the trimer fraction are listed. If no trimeric fraction was observed, then the oligomeric state of the dominant oligomeric species is provided. If the total yield before size-exclusion chromatography was <0.1 mg/liter, then oligomeric state is listed as not determined (N.D.). Yield shown is for the specified oligomeric state. When no binding was observed for 1 mM Fab, the K D is shown as >1000 nM; when total yield was <0.1 mg/liter, then the value for K D is not applicable (N/A). For site II, palivizumab (Paliv); motavizumab (Mota). Physical stability refers to D25 reactivity retained after exposure to various physical extremes. There were 10 cycles of freeze-thaw. N/A, not applicable. mean neutralizing titers of 911 and 1274 EC 50 for AM22 and D25 complexes, respectively, roughly double that of postfusion at 10 mg/ml and comparable to those elicited by postfusion at 20 mg/ml (Fig. 3A) . These findings suggested that the very high titers elicited by immunization with RSV F variants stabilized in the prefusion state, especially DS-Cav1, were a result of antibodies targeting antigenic site Ø.
To examine the generality of site Ø elicitation, we immunized rhesus macaques with DS-Cav1, DS, and postfusion forms of RSV F, injecting each macaque with 50 mg RSV F mixed with 500 mg poly-ICLC adjuvant at weeks 0 and 4 and measured the ability of week 2, 4, 6, 8, 10, and 14 sera to inhibit RSV infection. Formulated proteins retained their expected antigenic profiles as measured by D25 binding to material from the injectate ( fig. S9 ). At week 6, DS and DS-Cav1 elicited geometric mean titers of 1222 and 2578 EC 50 , respectively, roughly 5 and 10 times those of postfusion F (287 EC 50 ) (Fig. 3B) . By week 8, geometric mean titers of DS-Cav1 were roughly 70 times those elicited by postfusion F against the homologous RSV subtype A and more than 80 times titers against RSV subtype B ( fig. S10  and table S4) . Overall, these results demonstrate a conservation of the relative immunogenicity for the different forms of RSV F immunogen between mice and primates, with DS-Cav1 eliciting RSV-protective titers many times the protective threshold in a primate immune system against both major RSV subtypes.
Optimization of RSV F Protective Responses
The interplay among design, physical and antigenic properties, atomic-level structure, and immunogenicity provides a basis for further optimization of RSV vaccine candidates (35) figure S8 . (C) Atomic-level details are shown in stick representation, colored the same as in Fig. 2 , with regions of RSV F that change conformation between prefusion and postfusion conformation in red and blue, and those that remain constant in gray. Carbon atoms for stabilizing mutations are colored red. In Cav1 (pH 5.5) and in DS-Cav1 (pH 5.5) novel features were observed involving the interaction of the C terminus of the F 2 peptide with a sulfate ion and the fusion peptide. In the DS-Cav1-TriC structure, the D486H-E487Q-F488W-D489H mutations interact with the two neighboring protomers (colored tan and pink) around the trimer axis.
www.sciencemag.org SCIENCE VOL 342 1 NOVEMBER 2013 responses, one can correlate antigenic and physical properties (Table 1) with immunogenicity (Fig. 3) . Such correlations indicate that increasing site Ø stability to physical extremes should increase protective titers elicited upon immunization (Fig. 4A) (36) . Similarly, correlations between various conformational states or regions of RSV F (Fig. 2) and immunogenicity (Fig. 3) provide design insight into the conformation and regions of RSV F that provide the most protective responses. Specifically, enhancing structural mimicry of antigenic site Ø in its D25-bound conformation appears to be a promising strategy for improving protective antibody responses (Fig. 4B) .
We should also be able to estimate the degree to which improvement can be obtained relative to a particular parameter. For example, once a correlation has been established between physical stability or structural mimicry and protective responses, physical stability can be maximized (e.g., to 100% retention of D25 binding) or structural mimicry idealized (e.g., to exact mimicry of the D25-bound conformation) to gain an estimate of the maximal improvement of the elicited protective response relative to that particular parameter. The results (Fig. 4, A and B) suggest that increased structural mimicry would likely not have much effect on immunogenicity but that additional physical stabilization of antigenic site Ø might improve the protective titers by up to fourfold. Independent parameters such as adjuvant, multimerization, delivery vehicle, or immunization regimen offer further avenues for improvement of the elicited response (37) .
To quantify elicited binding responses, we coupled different variants of RSV F to an Octet biosensor tip and measured their reactivity with elicited sera (Fig. 4C ). "Self-reactive" binding responses (with DS-Cav1, DS, or postfusion F on the biosensor tip and sera from animals immunized with DS-Cav1, DS, or postfusion F, respectively) were comparable for DS-Cav1, DS, and postfusion F. To provide insight into the binding responses relative to surfaces that were either shared or unique to DS-Cav1, DS, and postfusion F, we measured "cross-reactive" binding responses, for example, with DS-Cav1 on the biosensor tip and sera from animals immunized with DS or postfusion F, as well as binding responses with "preabsorbed" sera, to which different forms of RSV F had been added (Fig. 4C) . We calculated the shared and unique surface areas, computed from crystal structures of DS-Cav1, DS, and postfusion F ( fig. S11 and table S3 ), and analyzed these relative to the 36 measured binding responses in Fig. 4C . Strong correlation was observed between binding responses and calculated surface areas (Fig. 4D) . Several outliers involved surfaces unique to DS-Cav1, surfaces that likely comprise antigenic site Ø. Together the results indicate that the quantity of elicited binding antibody was, to a first approximation, proportional to the surface area of the immunogen, independent of whether that immunogen was DS-Cav1, DS, or postfusion F; within this overall similarity, antigenic site Ø elicited~2 times the titer of binding antibody relative to its surface area. Overall, elicited EC 50 titers did not correlate with antigenic responses measured against either prefusion or postfusion forms of RSV F but did correlate with the level of prefusion-specific responses, either measured as a difference or as a ratio (P = 0.005) between prefusion-specific and postfusion-specific RSV F-directed responses (Fig. 4E) (38) ; the steep slope of this correlation likely reflects the substantially higher neutralization potency observed for prefusion-specific antibodies that target antigenic site Ø (7, 39) .
Structural Vaccinology
Structural biology can be used in vaccine development to identify key sites by which to disable a pathogen, to pinpoint residue substitutions that inactivate toxoids, to stabilize select conformations of a subunit antigen, and to determine antibodyantigen complexes, which serve as the basis for epitope-specific strategies of elicitation. Notably, atomic-level control of antigenicity increasingly appears to be within the reach of structure-based design (16, 40, 41) . With complex pathogens like malaria or meningoccocus, antibody-mediated neutralizing activity can be directed against many potential antigens, and vaccine discovery has focused on identifying the best target antigen by methods including genomic analysis or "reverse vaccinology" (42) (43) (44) (45) . However, for pathogens such as HIV-1, influenza, or RSV, where neutralizing antibodies act almost exclusively through one or two envelope glycoproteins, a site-or supersitespecific strategy might have advantages. Specifically, a viral site of vulnerability to neutralizing antibody may be more amenable to structure-based design than a viral subunit, while also retaining a higher level of immunogenicity than an epitopespecific scaffold (46) .
With site-specific vaccine strategies, selection of an appropriate target site is of crucial importance. Elicitation frequency, breadth, and potency are key considerations. Antigenic sites that comprise multiple overlapping epitopes of frequently elicited antibodies may be good targets, because of their expected capacity to elicit high levels of reactive antibodies in the general population. In terms of breadth, site Ø is among the most divergent of the antigenic sites on RSV; however, site Ø-directed antibodies such as D25 are capable of neutralizing most human RSVs, likely because of the relatively low genetic diversity of F among circulating human RSV strains, and both subtype A and B neutralizing activity was potently induced by the stabilized RSV F glycoproteins reported here (table S4) . Potency played a key role in our selection of site Ø as a vaccine target, and antigenic analysis of the elicited response (Fig. 4E ) indicated potency of elicited antibodies to be crucial to the success of our site Ø-focused approach (47) . Whether the "neutralizationsensitive site" strategy employed here will have success in other contexts thus depends on virusspecific factors such as circulating viral diversity and required level of neutralizing activity to achieve protection. Nonetheless, many of the lessons learned from our efforts with RSV, such as the importance of examining natural human immune responses and of selecting an appropriate target site, are generally applicable. S7 ). 26. The inability to express potential interchain double-cysteine substitutions, despite reasonable modeling in the mature prefusion F 1 F 2 structure, may indicate that RSV F 0 protomers, before cleavage and removal of peptide 27, adopt substantially different interprotomer conformations. 27. Cavities in the D25-bound RSV F structure were visualized with PyMol using the "Cavities & Pockets Only" option for Surface settings. Amino acid substitutions designed to fill the resulting cavities were identified using the Mutagenesis wizard. 28. M. Pancera et al., PLOS ONE 8, e55701 (2013). 29. The engineered RSV F variants had Ca-root mean square deviations from the D25-bound conformation of 0.7 to 1.5 Å and from the postfusion conformation of approximately 30 Å. 30. Crystallized DS retained~20% of its D25 recognition relative to crystallized Cav1 (normalized to motavizumab recognition) after 4 months at 20°C, thereby indicating that the crystallized DS was both capable of recognizing D25 as well as converting to a conformation incompatible with D25 binding. By contrast, soluble DS lost all recognition of D25 after 2 months of incubation at 4°C in PBS. We were unable to crystallize DS, which had been heat triggered at 50°C, despite the heat-triggered DS retaining a trimeric state on size exclusion chromatography. Table 1 , is compared with elicited RSV-protective titers from Fig. 3 (vertical axis). (B) Structural mimicry of site Ø versus immunogenicity. Structural mimicry (horizontal axis) is the root-mean-square deviation of atom distances between different unbound RSV F structures (Fig. 2) and the D25-bound RSV F structure for all atoms within 10 Å of D25. This is compared with elicited RSVneutralizing titers from www.sciencemag.org SCIENCE VOL 342 1 NOVEMBER 2013
